Topic: Health

Scientists have developed a new drug that nearly doubles survival rates for patients with advanced pancreatic cancer. The drug targets a specific genetic mutation that drives most pancreatic cancers.

Pancreatic cancer is one of the deadliest types of cancer. For patients diagnosed between 2015 and 2021, about 97% died within five years. This is because there are no effective screening tests, and the cancer rarely causes noticeable symptoms in its earliest stages. By the time a patient experiences signs like jaundice or abdominal pain, the cancer has often already spread to other organs.

For decades, scientists thought it was impossible to target the central mechanism that causes most pancreatic cancers. However, this narrative is rapidly changing with a new drug called daraxonrasib.

Daraxonrasib is taken daily by mouth and works by attaching to a molecule in cells that helps fold proteins into their final 3D structures. This protein complex then binds to the active KRAS protein and shuts down its ability to signal cancer cells to multiply.

The company developing the drug, Revolution Medicines, presented results from its Phase 3 clinical trial of 500 patients with metastatic pancreatic cancer who had received prior treatment. Compared to standard chemotherapy, daraxonrasib nearly doubled overall survival from 6.7 months to 13.2 months after diagnosis. Overall, daraxonrasib reduced the risk of death for metastatic pancreatic cancer patients by 60%.

The most common side effect is a prominent skin rash, which affected more than 86% of patients in the study. However, patients taking daraxonrasib were far less likely to stop treatment due to severe side effects compared to chemotherapy, and they had improved quality of life with reduced pain.

Why It Matters

This breakthrough could save countless lives in India where pancreatic cancer is a growing concern. It also highlights the importance of targeted therapy in treating complex diseases.

Key Facts

• The new drug daraxonrasib nearly doubles survival rates for patients with advanced pancreatic cancer.
• Daraxonrasib targets a specific genetic mutation that drives most pancreatic cancers.
• The Phase 3 clinical trial involved 500 patients with metastatic pancreatic cancer who had received prior treatment.
• Standard chemotherapy has limited effectiveness in treating pancreatic cancer due to the development of resistance by cancer cells.
• Pancreatic cancer is one of the deadliest types of cancer, with a 5-year survival rate of about 97% for patients diagnosed between 2015 and 2021.

Key Terms

KRAS

A gene that codes for proteins that function as switches that turn cell growth on and off.

Implications

This breakthrough could save countless lives in India where pancreatic cancer is a growing concern. It also highlights the importance of targeted therapy in treating complex diseases.